Fourth quarter 2025 total revenues were approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million. Full year 2025 total revenues were approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million. Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit. Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing, with completion of enrollment and selection of the recommended Phase 2 dose anticipated in the second half of 2026. Preliminary data from the R289 dose expansion phase are expected to be shared by the end of 2026. Updated data from the R289 dose escalation phase showed 33% (6/18) of evaluable transfusion-dependent patients achieved red blood cell transfusion independence (RBC-TI 8 weeks) at 500 mg QD and higher doses. Pralsetinib demonstrated robust and durable activity against RET fusion-positive solid tumors, including GI tumors, with an overall response rate (ORR) of 67% (26/39) in the efficacy evaluable population from the TAPISTRY study. Median overall survival (OS) for pralsetinib in metastatic RET fusion-positive NSCLC was 44.3 months for the overall patient population, with U.S. patients showing a longer median OS of 62.4 months. The U.S. FDA approved a Prior Approval supplemental New Drug Application for GAVRETO, updating the U.S. Prescribing Information to add a boxed warning regarding serious infections. Rigel met its postmarketing commitment for GAVRETO from its September 2020 accelerated approval. A paper detailing final 5-year results for olutasidenib in R/R mIDH1 AML was published, supporting durable responses and a manageable safety profile. Cash, cash equivalents and short-term investments as of December 31, 2025, were $155.0 million, compared to $77.3 million as of December 31, 2024. For 2026, Rigel anticipates total revenues of approximately $275 to $290 million, including net product sales of $255 to $265 million, and expects to report positive net income for the full year.